EGAGenomicsCancer Genomicshttps://ega-archive.org/studies/EGAS00001007086EGAEGA study EGAS00001007086Whole exome and RNA sequencing data from urothelial bladder cancer patients treated with anti-PD-(L)1EGArestrictedimprinted and ancient gene protein, B7H1, CD274, B7 homolog 1, Programmed death ligand 1, primary cancer, Malignant Neoplasm, Malignancy, Neoplasms, Benign Neoplasm, Benign Neoplasms, Cancers, PD-L1, Tumor, Ximpact, Malignant, malignant tumor, impact-a, Neoplasias, MT, Benign, PDCD1LG1, PDCD1L1, malignant neoplasm, B7-H, Neoplasm, IMPACT, imprinted and ancient gene protein homolog, PDCD1 ligand 1, Malignancies, E430016J11Rik, B7-H1, RWDD5, PDL1, Neoplasia, Cancer, Tumors, Malignant Neoplasms.Biological Markers, Viral Marker, PD L1 Inhibitor, Surrogate Endpoints, RNA Sequence Determination, Laboratory, Sequence Determination, RNA Sequence, Addresses, Biochemical, Endpoint, Tumor, Serum, ter, Readability, Laboratory Markers, diseases, Biological, 10.5, diseases and disorders, Whole Transcriptome, Transcriptome Sequencing, PD L1 Inhibitors, Analysis, 10.9, treatment, PD-1 Inhibitors, human disease, F, Programmed Death-Ligand 1 Inhibitors, DmelCG2328, Analyses, Determination, long, Complete Exome Sequencing, Whole Transcriptome Sequencing, hypoplasia, V, Sequence Determinations, Immune, Markers, malignant neoplasm, Bsg75C, PD-L1 Inhibitor, Viral Markers, disease management, Therapies, Homo sapiens disease, urothelial carcinoma, Malignancies, Tumors, Therapy, Checkpoint Blockade, Viral, CTLA-4 Inhibitors, Surrogate Endpoint, Exome, Biochemical Markers, Biologic Marker, transitional cell car. -uroth., Determinations, Immune Checkpoint Blockers, Benign, CTLA 4 Inhibitor, Term, Marker, Diseases, VI, Programmed Cell Death Protein 1 Inhibitors, PD-1, Complete Transcriptome, 20.35, Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors, Drives, End Points, transitional cell carcinoma of the urothelial tract, Benign Neoplasms, Immunologic, PD 1 Inhibitor, Laboratory Marker, Treatments, Malignant Neoplasms, Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor, disease, metastatic, Patient, antagonists and inhibitors, Biochemical Marker, Whole Exome Sequencing, eve2, Checkpoint Inhibitors, Inhibitor, Transcriptome Sequencings, CG2328, 14.10, other disease, Clinical Markers, Complete Exome, Clinical Marker, Neoplasms, transitional cell carcinoma of the urinary tract, Benign Neoplasm, PD-L1 Inhibitors, Malignant, PD 1 PD L1 Blockade, antibodies., Surrogate End Points, Surrogate Markers, Blockade, reduced, disease or disorder, even, tiny, PD-1 Inhibitor, Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor, Biomarker, WES, Complete, Exome Sequencings, Clinical, Malignancy, Biological Marker, inhibiteur, Checkpoint Blockers, Sequencing, Programmed Death Ligand 1 Inhibitors, non-neoplastic, Neoplasias, CTLA-4 Inhibitor, Immune Checkpoint Blockade, DmelCG4216, Immunologic Markers, Whole Exome, inhibidor, RNA Sequence Analyses, Clients, Whole, PD-1-PD-L1, disorder, RNA Sequencing, Immunologic Marker, Biologic, Cancer, Sequence Analyses, small, PD-1-PD-L1 Blockade, inhibitors, RNA, Malignant Neoplasm, Complete Exome Sequencings, RNA Sequence Determinations, Serum Markers, disorders, End Point, inhibitor, Checkpoint Inhibitor, medical condition, Client, Immune Marker, Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors, CTLA 4 Inhibitors, Exome Sequencing, MT, PD 1 Inhibitors, Surrogate End Point, Neoplasm, condition, Eve, EVE, Biologic Markers, antagonists, primary cancer, Serum Marker, Complete Transcriptome Sequencing, underdeveloped, Immune Checkpoint Inhibitor, Surrogate, Endpoints, CG4216, l(2)46Ce, Cancers, Understanding, Programmed Cell Death Protein 1 Inhibitor, malignant tumor, l(2)46Cg, Surrogate Marker, l(2)46CFj, l(2)46CFh, Uroepithelial carcinoma, Therapeutic, l(2)46CFp, Checkpoint Inhibition, RNA Sequence Analysis, Treatment, E(eve), Neoplasia, Immune Checkpoint Inhibition, l(2)46CFg, Immune MarkersfalseThe impact of mutational clonality in predicting the response to anti-PD-L1/PD-L1 in advanced urothelial cancerThe advent of immune checkpoint inhibitors (ICI) has radically changed the management and therapeutic treatment landscape for patients with cancer. It has been shown that the use of these inhibitors can result in long-term complete remissions even in cases with advanced stages of the disease. However, only a small fraction of patients respond to the treatment. A better understanding of which factors could drive this clinical benefit is fundamental to building more accurate predictive biomarkers and developing alternative therapeutic options for patients who are unlikely to benefit. In order to address this issue, we have generated and analyzed whole exome sequencing (WES) and RNA sequencing (RNASeq) data from a cohort of metastatic urothelial carcinoma patients (N = 27) treated with ICI such as anti-PD-(L)1 monoclonal antibodies.2023-05-29 15:37:03EGAS000010070869606EGAD00001010324EGAC00001003148